Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug
Executive Summary
Avillion – which seeks co-development deals for products that otherwise could languish in busy big pharma pipelines – is taking on development of Merck's early-stage psoriasis drug, M1095, despite originator Ablynx having opted out of a co-development arrangement with the German firm for the drug four years earlier.
You may also be interested in...
Novartis Confident Cosentyx Can Keep Competition At Bay
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab
Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.